 Brett Stevens
Concepts (235)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 24 | 2024 | 591 | 3.880 |
Why?
| | Neoplastic Stem Cells | 15 | 2025 | 377 | 1.950 |
Why?
| | Myelodysplastic Syndromes | 4 | 2020 | 128 | 1.820 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 12 | 2025 | 1558 | 1.440 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 13 | 2025 | 215 | 1.430 |
Why?
| | Proto-Oncogene Proteins c-cbl | 3 | 2014 | 11 | 1.030 |
Why?
| | Azacitidine | 8 | 2024 | 139 | 0.980 |
Why?
| | Sulfonamides | 11 | 2025 | 494 | 0.940 |
Why?
| | Drug Resistance, Neoplasm | 7 | 2025 | 744 | 0.870 |
Why?
| | Interleukin-3 Receptor alpha Subunit | 2 | 2019 | 17 | 0.800 |
Why?
| | Flow Cytometry | 3 | 2020 | 1140 | 0.740 |
Why?
| | Hematopoietic Stem Cells | 2 | 2021 | 379 | 0.630 |
Why?
| | Reactive Oxygen Species | 2 | 2020 | 582 | 0.610 |
Why?
| | Salvage Therapy | 1 | 2019 | 133 | 0.590 |
Why?
| | Proto-Oncogene Proteins c-fyn | 2 | 2014 | 12 | 0.580 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2018 | 324 | 0.580 |
Why?
| | Multiple Myeloma | 3 | 2024 | 125 | 0.510 |
Why?
| | Immunotherapy, Adoptive | 1 | 2019 | 295 | 0.500 |
Why?
| | Mice, Inbred NOD | 7 | 2020 | 586 | 0.500 |
Why?
| | Neoplasms, Plasma Cell | 1 | 2015 | 7 | 0.500 |
Why?
| | Leukocytosis | 1 | 2015 | 32 | 0.500 |
Why?
| | Clonal Evolution | 1 | 2015 | 38 | 0.480 |
Why?
| | Mice, SCID | 5 | 2020 | 350 | 0.480 |
Why?
| | Computational Biology | 1 | 2019 | 595 | 0.460 |
Why?
| | Rho Guanine Nucleotide Exchange Factors | 1 | 2014 | 22 | 0.450 |
Why?
| | Oxidative Phosphorylation | 6 | 2024 | 184 | 0.450 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2020 | 955 | 0.450 |
Why?
| | Interferon Regulatory Factors | 3 | 2024 | 33 | 0.440 |
Why?
| | Proto-Oncogene Proteins c-myc | 3 | 2024 | 130 | 0.430 |
Why?
| | Mutation | 3 | 2024 | 3682 | 0.410 |
Why?
| | Leukemia | 3 | 2020 | 228 | 0.410 |
Why?
| | Cell Proliferation | 4 | 2021 | 2337 | 0.410 |
Why?
| | Carrier Proteins | 1 | 2015 | 730 | 0.370 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2025 | 112 | 0.360 |
Why?
| | Nuclear Proteins | 1 | 2015 | 657 | 0.350 |
Why?
| | Glioblastoma | 1 | 2014 | 323 | 0.350 |
Why?
| | Neutrophils | 1 | 2015 | 1192 | 0.330 |
Why?
| | Neoplasm, Residual | 3 | 2024 | 119 | 0.300 |
Why?
| | Cell Self Renewal | 2 | 2019 | 52 | 0.300 |
Why?
| | Fatty Acids | 3 | 2020 | 415 | 0.290 |
Why?
| | Stem Cells | 3 | 2020 | 577 | 0.290 |
Why?
| | Humans | 40 | 2025 | 128019 | 0.280 |
Why?
| | Mice | 17 | 2025 | 16574 | 0.280 |
Why?
| | Animals | 20 | 2025 | 34487 | 0.260 |
Why?
| | Protein Kinase Inhibitors | 3 | 2025 | 875 | 0.250 |
Why?
| | Amino Acids | 2 | 2020 | 476 | 0.250 |
Why?
| | Ikaros Transcription Factor | 1 | 2024 | 21 | 0.230 |
Why?
| | Thalidomide | 1 | 2024 | 31 | 0.230 |
Why?
| | Cell Line, Tumor | 7 | 2025 | 3168 | 0.220 |
Why?
| | Tumor Cells, Cultured | 4 | 2022 | 930 | 0.210 |
Why?
| | Finland | 1 | 2023 | 90 | 0.210 |
Why?
| | Uncertainty | 1 | 2023 | 114 | 0.200 |
Why?
| | Electron Transport Complex II | 2 | 2019 | 24 | 0.200 |
Why?
| | Amino Acid Transport System ASC | 1 | 2022 | 12 | 0.190 |
Why?
| | Minor Histocompatibility Antigens | 1 | 2022 | 46 | 0.190 |
Why?
| | Trans-Activators | 2 | 2021 | 381 | 0.180 |
Why?
| | Nuclear Receptor Co-Repressor 2 | 1 | 2020 | 15 | 0.180 |
Why?
| | Bone Marrow Diseases | 1 | 2020 | 19 | 0.180 |
Why?
| | Protein Synthesis Inhibitors | 1 | 2020 | 41 | 0.170 |
Why?
| | Proto-Oncogene Proteins c-ets | 1 | 2020 | 53 | 0.170 |
Why?
| | RNA Splicing Factors | 1 | 2020 | 52 | 0.170 |
Why?
| | Lipase | 1 | 2020 | 64 | 0.170 |
Why?
| | STAT3 Transcription Factor | 1 | 2022 | 190 | 0.170 |
Why?
| | Mitochondria | 2 | 2024 | 847 | 0.170 |
Why?
| | Neoplasms | 1 | 2014 | 2460 | 0.170 |
Why?
| | Oxidation-Reduction | 4 | 2019 | 1001 | 0.170 |
Why?
| | Aged, 80 and over | 6 | 2024 | 7029 | 0.170 |
Why?
| | Germ-Line Mutation | 1 | 2020 | 138 | 0.160 |
Why?
| | Signal Transduction | 5 | 2022 | 4812 | 0.160 |
Why?
| | Decision Support Systems, Clinical | 1 | 2022 | 205 | 0.160 |
Why?
| | Leukopoiesis | 1 | 2019 | 11 | 0.160 |
Why?
| | Lentivirus | 1 | 2019 | 52 | 0.160 |
Why?
| | NADPH Oxidase 2 | 1 | 2019 | 38 | 0.160 |
Why?
| | Myeloid Progenitor Cells | 1 | 2019 | 18 | 0.160 |
Why?
| | Cytarabine | 1 | 2019 | 56 | 0.160 |
Why?
| | Histone Deacetylases | 1 | 2020 | 210 | 0.150 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2019 | 90 | 0.150 |
Why?
| | Homeostasis | 2 | 2021 | 605 | 0.150 |
Why?
| | Thrombocytopenia | 1 | 2020 | 184 | 0.150 |
Why?
| | Bone Marrow | 2 | 2020 | 267 | 0.150 |
Why?
| | Mitochondrial Proteins | 2 | 2018 | 245 | 0.150 |
Why?
| | Protein Biosynthesis | 1 | 2020 | 397 | 0.150 |
Why?
| | Calcium | 1 | 2024 | 1182 | 0.150 |
Why?
| | Phosphoproteins | 1 | 2020 | 328 | 0.150 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2024 | 840 | 0.150 |
Why?
| | Cell Survival | 3 | 2022 | 1073 | 0.150 |
Why?
| | RNA Interference | 3 | 2014 | 441 | 0.150 |
Why?
| | Stress, Physiological | 1 | 2021 | 411 | 0.150 |
Why?
| | Cysteine | 1 | 2019 | 182 | 0.150 |
Why?
| | Cation Transport Proteins | 1 | 2019 | 130 | 0.140 |
Why?
| | Survival Rate | 2 | 2019 | 1870 | 0.140 |
Why?
| | Aged | 8 | 2024 | 21892 | 0.140 |
Why?
| | Arthritis, Experimental | 1 | 2019 | 128 | 0.140 |
Why?
| | Female | 16 | 2024 | 68016 | 0.140 |
Why?
| | Proto-Oncogene Proteins | 1 | 2021 | 632 | 0.140 |
Why?
| | Male | 12 | 2024 | 62757 | 0.140 |
Why?
| | Repressor Proteins | 1 | 2020 | 399 | 0.140 |
Why?
| | Transplantation, Heterologous | 2 | 2014 | 187 | 0.130 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2018 | 189 | 0.130 |
Why?
| | Cells, Cultured | 3 | 2019 | 4006 | 0.130 |
Why?
| | Tumor Burden | 2 | 2016 | 283 | 0.130 |
Why?
| | Neoplasm Proteins | 2 | 2016 | 419 | 0.130 |
Why?
| | Gene Expression Regulation, Leukemic | 1 | 2016 | 50 | 0.130 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2016 | 67 | 0.130 |
Why?
| | Oncogene Proteins | 1 | 2016 | 52 | 0.130 |
Why?
| | HEK293 Cells | 2 | 2019 | 681 | 0.130 |
Why?
| | Gene Expression | 1 | 2020 | 1454 | 0.120 |
Why?
| | Autoimmune Diseases | 1 | 2019 | 423 | 0.120 |
Why?
| | Methyltransferases | 1 | 2016 | 69 | 0.120 |
Why?
| | Myeloid-Lymphoid Leukemia Protein | 1 | 2016 | 71 | 0.120 |
Why?
| | Oligomycins | 1 | 2014 | 7 | 0.120 |
Why?
| | Chromosome Aberrations | 1 | 2015 | 148 | 0.120 |
Why?
| | Cytokines | 3 | 2020 | 1984 | 0.120 |
Why?
| | Mitochondrial Proton-Translocating ATPases | 1 | 2014 | 17 | 0.120 |
Why?
| | Biomarkers, Tumor | 2 | 2019 | 1175 | 0.120 |
Why?
| | Retrospective Studies | 4 | 2024 | 14404 | 0.110 |
Why?
| | fms-Like Tyrosine Kinase 3 | 1 | 2014 | 47 | 0.110 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2015 | 313 | 0.110 |
Why?
| | DNA Mutational Analysis | 1 | 2015 | 384 | 0.110 |
Why?
| | Carmustine | 1 | 2014 | 50 | 0.110 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2016 | 125 | 0.110 |
Why?
| | Dacarbazine | 1 | 2014 | 94 | 0.110 |
Why?
| | Antineoplastic Agents, Alkylating | 1 | 2014 | 69 | 0.110 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 1934 | 0.110 |
Why?
| | Tumor Suppressor Proteins | 1 | 2016 | 313 | 0.110 |
Why?
| | Spheroids, Cellular | 1 | 2014 | 73 | 0.110 |
Why?
| | cdc42 GTP-Binding Protein | 1 | 2013 | 23 | 0.110 |
Why?
| | Glucose | 1 | 2018 | 983 | 0.100 |
Why?
| | Follow-Up Studies | 2 | 2019 | 4853 | 0.100 |
Why?
| | Middle Aged | 6 | 2024 | 30812 | 0.100 |
Why?
| | Antineoplastic Agents | 3 | 2024 | 2041 | 0.100 |
Why?
| | Fusion Proteins, bcr-abl | 2 | 2014 | 64 | 0.100 |
Why?
| | Inflammation | 2 | 2021 | 2646 | 0.100 |
Why?
| | Adaptation, Physiological | 1 | 2016 | 513 | 0.100 |
Why?
| | Adipose Tissue | 1 | 2016 | 589 | 0.100 |
Why?
| | Tamoxifen | 1 | 2013 | 200 | 0.100 |
Why?
| | Liver | 1 | 2020 | 1826 | 0.100 |
Why?
| | Membrane Proteins | 1 | 2018 | 1105 | 0.100 |
Why?
| | Biopsy | 1 | 2015 | 1077 | 0.100 |
Why?
| | Blotting, Western | 1 | 2014 | 1169 | 0.090 |
Why?
| | Mice, Inbred C57BL | 5 | 2021 | 5268 | 0.090 |
Why?
| | Blast Crisis | 2 | 2025 | 33 | 0.090 |
Why?
| | Arthritis, Rheumatoid | 1 | 2019 | 1088 | 0.090 |
Why?
| | Insulin Resistance | 1 | 2018 | 1164 | 0.080 |
Why?
| | Succinate Dehydrogenase | 2 | 2019 | 43 | 0.080 |
Why?
| | Lymphoid Progenitor Cells | 1 | 2008 | 11 | 0.080 |
Why?
| | Young Adult | 3 | 2021 | 12281 | 0.080 |
Why?
| | Prognosis | 3 | 2024 | 3766 | 0.080 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2008 | 69 | 0.080 |
Why?
| | Energy Metabolism | 3 | 2019 | 831 | 0.070 |
Why?
| | Protein Binding | 1 | 2014 | 2105 | 0.070 |
Why?
| | Fresh Water | 1 | 2008 | 54 | 0.070 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2018 | 228 | 0.070 |
Why?
| | Disease Models, Animal | 4 | 2020 | 3936 | 0.060 |
Why?
| | Adult | 4 | 2024 | 35176 | 0.060 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2008 | 278 | 0.060 |
Why?
| | Mice, Knockout | 3 | 2016 | 2757 | 0.060 |
Why?
| | Biodiversity | 1 | 2008 | 373 | 0.060 |
Why?
| | Treatment Outcome | 3 | 2024 | 10110 | 0.050 |
Why?
| | Antigens, CD34 | 1 | 2023 | 89 | 0.050 |
Why?
| | Disease Progression | 2 | 2023 | 2598 | 0.050 |
Why?
| | RNA, Small Interfering | 2 | 2014 | 569 | 0.050 |
Why?
| | Induction Chemotherapy | 1 | 2021 | 70 | 0.050 |
Why?
| | Bacteria | 1 | 2008 | 812 | 0.050 |
Why?
| | Polymerase Chain Reaction | 1 | 2024 | 1020 | 0.050 |
Why?
| | Breast Neoplasms | 1 | 2013 | 2131 | 0.040 |
Why?
| | Megakaryocytes | 1 | 2020 | 31 | 0.040 |
Why?
| | Spliceosomes | 1 | 2020 | 46 | 0.040 |
Why?
| | Proteasome Inhibitors | 1 | 2020 | 42 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2020 | 157 | 0.040 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2020 | 195 | 0.040 |
Why?
| | Adolescent | 1 | 2019 | 20158 | 0.040 |
Why?
| | Niacinamide | 1 | 2020 | 73 | 0.040 |
Why?
| | Drug Synergism | 1 | 2020 | 356 | 0.040 |
Why?
| | Cytogenetic Analysis | 1 | 2019 | 33 | 0.040 |
Why?
| | Tricarboxylic Acids | 1 | 2018 | 10 | 0.040 |
Why?
| | RNA Splicing | 1 | 2020 | 262 | 0.040 |
Why?
| | Ketoglutaric Acids | 1 | 2018 | 15 | 0.040 |
Why?
| | Remission Induction | 1 | 2019 | 267 | 0.040 |
Why?
| | Protein Transport | 1 | 2020 | 420 | 0.040 |
Why?
| | Mice, Transgenic | 2 | 2018 | 2066 | 0.040 |
Why?
| | Cell Cycle | 1 | 2021 | 580 | 0.040 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2024 | 1343 | 0.040 |
Why?
| | Cohort Studies | 2 | 2020 | 5378 | 0.040 |
Why?
| | Forkhead Transcription Factors | 1 | 2019 | 181 | 0.040 |
Why?
| | Apoptosis | 2 | 2018 | 2425 | 0.040 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2020 | 809 | 0.040 |
Why?
| | Inflammation Mediators | 1 | 2020 | 495 | 0.040 |
Why?
| | Biological Transport | 1 | 2018 | 396 | 0.040 |
Why?
| | Machine Learning | 1 | 2022 | 442 | 0.030 |
Why?
| | Glutathione | 1 | 2019 | 340 | 0.030 |
Why?
| | Diet, High-Fat | 1 | 2018 | 238 | 0.030 |
Why?
| | Glycolysis | 1 | 2018 | 293 | 0.030 |
Why?
| | Adenosine Triphosphate | 1 | 2019 | 469 | 0.030 |
Why?
| | NADP | 1 | 2016 | 43 | 0.030 |
Why?
| | Genetic Testing | 1 | 2019 | 428 | 0.030 |
Why?
| | Tumor Microenvironment | 1 | 2020 | 620 | 0.030 |
Why?
| | Gonads | 1 | 2016 | 23 | 0.030 |
Why?
| | CD36 Antigens | 1 | 2016 | 35 | 0.030 |
Why?
| | Cytoprotection | 1 | 2016 | 50 | 0.030 |
Why?
| | Deoxyglucose | 1 | 2016 | 49 | 0.030 |
Why?
| | Myeloid Ecotropic Viral Integration Site 1 Protein | 1 | 2016 | 10 | 0.030 |
Why?
| | Sesquiterpenes | 1 | 2016 | 52 | 0.030 |
Why?
| | Lipolysis | 1 | 2016 | 40 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 2016 | 257 | 0.030 |
Why?
| | Metabolome | 1 | 2018 | 319 | 0.030 |
Why?
| | Lipid Metabolism | 1 | 2018 | 491 | 0.030 |
Why?
| | Sirolimus | 1 | 2016 | 189 | 0.030 |
Why?
| | Immunity, Innate | 1 | 2021 | 801 | 0.030 |
Why?
| | Dihydrolipoyllysine-Residue Acetyltransferase | 1 | 2014 | 6 | 0.030 |
Why?
| | Ketone Oxidoreductases | 1 | 2014 | 7 | 0.030 |
Why?
| | Immunophenotyping | 1 | 2016 | 309 | 0.030 |
Why?
| | Imatinib Mesylate | 1 | 2014 | 67 | 0.030 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2014 | 67 | 0.030 |
Why?
| | Superoxides | 1 | 2014 | 196 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2021 | 1896 | 0.030 |
Why?
| | Up-Regulation | 1 | 2016 | 822 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2020 | 1354 | 0.030 |
Why?
| | Recurrence | 1 | 2016 | 993 | 0.030 |
Why?
| | Homeodomain Proteins | 1 | 2016 | 489 | 0.020 |
Why?
| | Estrogen Receptor alpha | 1 | 2013 | 132 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2020 | 2261 | 0.020 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2014 | 430 | 0.020 |
Why?
| | Insulin | 1 | 2018 | 2316 | 0.020 |
Why?
| | Biomarkers | 1 | 2019 | 3874 | 0.020 |
Why?
| | New York | 1 | 2008 | 124 | 0.020 |
Why?
| | Principal Component Analysis | 1 | 2008 | 182 | 0.020 |
Why?
| | Geography | 1 | 2008 | 186 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2008 | 541 | 0.020 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2008 | 519 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2008 | 771 | 0.010 |
Why?
| | Prospective Studies | 1 | 2016 | 7035 | 0.010 |
Why?
| | Phylogeny | 1 | 2008 | 838 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2008 | 2820 | 0.010 |
Why?
| | Child | 1 | 2020 | 20636 | 0.010 |
Why?
|
|
Stevens's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|